Sign inJoin free

Watch / Mergers & Acquisitions

Bid buffet: Traders circle ASX takeover targets

28 Apr 20268:52

Bid buffet: Traders circle ASX takeover targets

General information only. ausbiz videos are general information only, produced by Ausbiz TV Pty Ltd, a media business that doesn’t give financial advice. They don’t take into account your objectives, financial situation or needs. Consider whether it’s right for you and read the PDS and TMD before acting on anything you watch.

About this video

Key points

  • Atlas Arteria (ASX:ALX) bid from IFM seen as underpriced versus past offer

  • European Lithium (ASX:EUR)–Critical Metals deal viewed as structurally attractive but hedge‑intensive

  • Australian Strategic Materials (ASX:ASM) options collapse seen as a cleaner, cash‑based play

  • Monash IVF (ASX:MVF) rejection of $0.90 offer sets stage for future hostile or higher bids - Large Asian private equity funds expected, in Sproats’ view, to drive more Australian buyouts

Nic Sproats from Harvest Lane Asset Management sees a busy period ahead for merger arbitrage, with several Australian and global deals creating opportunity. Sproats points to the contested play for Atlas Arteria (ASX:ALX), where IFM Global Investors has lifted its offer yet, in his view, the pricing around $4.75–$5.10 per share is unlikely to draw board support given IFM’s prior $8.10 approach and ongoing strategic tensions over Atlas Arteria’s M&A ambitions.

In resources, Sproats highlights European Lithium (ASX:EUR) and its complex merger with Nasdaq-listed Critical Metals, characterising it as effectively a self-buyout that simplifies the joint venture structure and could be lucrative for those able to hedge Nasdaq exposure. He also notes Australian Strategic Materials (ASX:ASM), where Energy Fuels’ bid has secured FIRB approval and the options collapse offers an attractive all‑cash angle compared with the scrip-heavy equity component.

Sproats remains focused on Monash IVF (ASX:MVF), where a $0.90 offer from Saltpans and Genesis has been rejected, leaving the share price around $0.74 and setting up potential hostile tactics later this year. He also flags record Asian private equity fundraising by EQT and Barings as a catalyst for more public‑to‑private activity in what he views as an undervalued Australian market.

More like this

We value your privacy

We use essential cookies to make the site work. Non-essential cookies help us improve the experience. You can accept or reject non-essential cookies. Privacy policy